Login to Your Account



AlphaCore Aiming High with Recombinant LCAT

By Marie Powers
Staff Writer

Wednesday, January 2, 2013

AlphaCore Pharma Inc. has maintained a low profile since its founding in 2007, befitting a biotech working in the rare orphan indication of familial LCAT deficiency. The inherited condition causes corneal opacities, anemia and renal disease due to the accumulation of LCAT substrates (unesterified cholesterol and phospholipid).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription